Recro Pharma, Inc. (REPH) Reached 1-Year Low on Jun, 29 at $4.91

June 29, 2018 - By Matthew Medley

Recro Pharma, Inc. (NASDAQ:REPH) Corporate Logo

Big Money Sentiment increased to 2.37 in Q1 2018. It has change of 0.87, from 2017Q4’s 1.5. The ratio is positive due to Recro Pharma, Inc. positioning: 5 sold and 14 reduced. 23 funds took positions and 22 increased positions. Investors holded 9.57 million in 2017Q4 but now own 10.95 million shares or 14.40% more.
Northern Trust Corp reported 0% in Recro Pharma, Inc. (NASDAQ:REPH). Brandywine Glob Inv Management Limited Com stated it has 41,500 shs. Bb&T Corp owns 0.01% invested in Recro Pharma, Inc. (NASDAQ:REPH) for 50,000 shs. Renaissance Technology Ltd Co reported 0% of its capital in Recro Pharma, Inc. (NASDAQ:REPH). Tower Capital Limited Liability Com (Trc) owns 7 shs or 0% of their US capital. Walleye Trading Lc owns 19,600 shs. 50,793 were reported by Goldman Sachs Grp. New York-based Bnp Paribas Arbitrage has invested 0% in Recro Pharma, Inc. (NASDAQ:REPH). Morgan Stanley invested in 0% or 65,155 shs. 1,196 are held by Ameritas Inv Prtnrs Inc. Barclays Public Limited Company owns 0% invested in Recro Pharma, Inc. (NASDAQ:REPH) for 4,974 shs. Rhumbline Advisers has invested 0% in Recro Pharma, Inc. (NASDAQ:REPH). Jump Trading Llc has invested 0.01% of its capital in Recro Pharma, Inc. (NASDAQ:REPH). Acadian Asset Limited Co holds 0% or 47,049 shs. Lyon Street Capital Lc holds 1.03 million shs or 3.64% of its capital.

Recro Pharma, Inc. had 7 selling transactions and 0 insider purchases since January 2, 2018. This’s net activity of $3.70 million. $1.09 million worth of Recro Pharma, Inc. (NASDAQ:REPH) shs were sold by Broadfin Healthcare Master Fund Ltd. SCP Vitalife Partners II LP had sold 4,732 shs worth $41,822 on Thursday, January 4. 7,500 shs were sold by Berelowitz Michael, worth $78,347 on Friday, March 9.

A yearly low was hit by Recro Pharma, Inc. (NASDAQ:REPH). Today’s price per share was $4.91. It’s 7.00 % below our $4.57. It was reported on Jun, 29 by Recro Pharma, Inc. (NASDAQ:REPH) has $100.69 million market cap. At $4.57 price target, the company’s valuation could be $7.05M less.

REPH is hitting $4.91 during the last trading session, after increased 2.29%.Currently Recro Pharma, Inc. is downtrending after 32.73% change in last June 29, 2017. REPH has 86,938 shares volume. REPH underperformed by 45.30% the S&P 500.

Recro Pharma, Inc. (NASDAQ:REPH)’s earnings report is expected on August, 9., Zacks reports. Analysts forecast $-1.35 EPS. That’s $0.87 down or 181.25 % from 2017’s earnings of $-0.48. Wall Street now sees 107.69 % negative EPS growth despite Recro Pharma, Inc. last quarter’s EPS of $-0.65.

Recro Pharma, Inc. (NASDAQ:REPH) Ratings Coverage

Total analysts of 4 have positions in Recro Pharma (NASDAQ:REPH) as follows: 4 rated it a “Buy”, 0 with “Sell” and 0 with “Hold”. The positive are 100%. The firm has $21.2500 highest while $1100 is the lowest PT. The average target $15.81 is 222.00% above the last ($4.91) price. Since February 13, 2018 according to StockzIntelligence Inc Recro Pharma has 5 analyst reports. The company rating was maintained by Oppenheimer on Thursday, May 10. On Tuesday, February 13 the company was initiated by Oppenheimer. On Thursday, April 19 the firm has “Buy” rating given by Berenberg. On Wednesday, February 28 the stock of Recro Pharma, Inc. (NASDAQ:REPH) has “Buy” rating given by Piper Jaffray.

For more Recro Pharma, Inc. (NASDAQ:REPH) news published recently go to:,,, or The titles are as follows: “SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Recro …” published on June 20, 2018, “UPCOMING DEADLINES: The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of KLIC …” on June 24, 2018, “REPH SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of Commencement of a Class …” with a publish date: June 13, 2018, “SHAREHOLDER ALERT – FLR REPH TAL HAIR: The Law Offices of Vincent Wong Reminds Investors of Important …” and the last “EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Recro Pharma, Inc. of a Class Action Lawsuit and a …” with publication date: June 10, 2018.

Recro Pharma, Inc., a specialty pharmaceutical company, engages in developing non-opioid products for the treatment of acute pain primarily in the United States.The company has $100.69 million market cap. The Company’s lead product candidate includes injectable meloxicam, which completed pivotal Phase III clinical trials for the treatment of post-operative pain.Last it reported negative earnings. The firm also provides Dex-IN, an intranasal formulation of dexmedetomidine that is in development stage for treating post-operative pain and peri-procedural pain; and Fadolmidine, alpha-2 agonist product for use in treating neuropathic pain.

Recro Pharma, Inc. (NASDAQ:REPH) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.